Dr. Alan Skarbnik, MD
Claim this profileNovant Health Presbyterian Medical Center
Affiliated Hospitals
Novant Health Presbyterian Medical Center
Novant Cancer Institute Charlotte
Clinical Trials Alan Skarbnik, MD is currently running
Rituximab vs Mosunetuzumab
for Follicular Lymphoma
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.
Recruiting
2 awards
Phase 3
13 criteria
Pirtobrutinib vs Ibrutinib
for Chronic Lymphocytic Leukemia
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treatment-naïve participants with CLL/SLL with 17p deletions. Participation could last up to six years for Part 1. Participation could last up to 2 years for Part 2.
Recruiting
2 awards
Phase 3
More about Alan Skarbnik, MD
Clinical Trial Related
6 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Alan Skarbnik, MD has experience with
- Pirtobrutinib
- Rituximab
- Fludarabine
- Cyclophosphamide
- JCAR017
- ClonoSEQ Assay
Breakdown of trials Alan Skarbnik, MD has run
Lymphoma
Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alan Skarbnik, MD specialize in?
Alan Skarbnik, MD focuses on Lymphoma and Non-Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved treating patients, or patients who are undergoing treatment.
Is Alan Skarbnik, MD currently recruiting for clinical trials?
Yes, Alan Skarbnik, MD is currently recruiting for 2 clinical trials in Charlotte North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Alan Skarbnik, MD has studied deeply?
Yes, Alan Skarbnik, MD has studied treatments such as Pirtobrutinib, Rituximab, Fludarabine.
What is the best way to schedule an appointment with Alan Skarbnik, MD?
Apply for one of the trials that Alan Skarbnik, MD is conducting.
What is the office address of Alan Skarbnik, MD?
The office of Alan Skarbnik, MD is located at: Novant Health Presbyterian Medical Center, Charlotte, North Carolina 28204 United States. This is the address for their practice at the Novant Health Presbyterian Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.